The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Promising results of the MorningSun trial: mosunetuzumab in various lymphoma subtypes
Tara Graff, DO, Mission Cancer and Blood, Des Moines, IA, briefly discusses the promising results of the MorningSun trial (NCT05207670), which is evaluating the safety and efficacy of mosunetuzumab in various lymphoma indications, including follicular lymphoma (FL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
